MedTrace Logo

Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey

NCT01188278 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 173

Last updated 2016-09-30

No results posted yet for this study

Summary

The purpose of this study is to determine predictive value of Hammersmith score on Complete Cytogenetic Response (CCyR).

Conditions

  • Leukemia, Myeloid, Chronic-Phase (CML-CP)

Interventions

DRUG

Imatinib

Drug being observed but not provided

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2013-01-31
Completion
2013-01-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01188278 on ClinicalTrials.gov